Navigation Links
Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
Date:4/28/2009

oduct candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as BPH. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials will not support approval for a marketing license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a marketing license has been applied, the risk that the results of a clinical trial may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
2. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
3. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
4. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
5. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
8. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
9. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
10. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to the ... internet on Monday, November 3, 2014 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
(Date:10/25/2014)... 24, 2014 Best Practices designed the ... with a forum for sharing insights about the ... a mechanism for creating and sharing solutions through ... findings from the Medical Affairs Consortium survey. ... for the first roundtable of the 2014-2015 Medical ...
(Date:10/22/2014)... 2014  Cephasonics, a technology-innovation leader with a game-changing ... (cQuest Ultrasound Box™-1), the first product in a new ... by Cephasonics for purchase by companies to rebrand with ... be showcasing the cQUB-1 for the first time at ... Chongqing, China from October 23 to ...
Breaking Medicine Technology:DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3
... SUPERIOR, Colo., Jan. 10, 2011 Key Equipment ... finance companies and an affiliate of KeyCorp (NYSE: ... entered into an exclusive, long term, program agreement with ... America is the U.S. distributor of Hitachi Medical Corporation,s ...
... Jan. 8, 2011 - Bayer HealthCare Pharmaceuticals has become aware ... pads, swabs and swabsticks manufactured by the Triad Group and ... safety, Bayer wants to ensure that U.S. patients and physicians ... The recall of the Triad Group alcohol ...
Cached Medicine Technology:Key Equipment Finance Enters Long-Term Program Agreement With Hitachi Medical Systems America 2Key Equipment Finance Enters Long-Term Program Agreement With Hitachi Medical Systems America 3Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products 2Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products 3
(Date:10/25/2014)... The proposed consolidation of all federally-filed ... December, when the U.S. Judicial Panel on Multidistrict Litigation ... Hearing Session Order issued by the Panel on October ... on December 4, 2014, in Charleston, South Carolina. The ... Xarelto Products Liability Litigation, No. 2592) , “Our Firm ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 TASC ... medical and other benefits account management services, announces ... help employers save on taxes, reduce administrative workload, ... provide tax savings and the efficient handling of ... the Suite that best meets their goals and ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
(Date:10/25/2014)... -- October,s shorter, darker days can trigger a type ... an expert. People affected by seasonal affective ... motivation and even have trouble getting out of bed. ... Dr. Angelos Halaris, a professor in the department of ... School of Medicine. "Seasonal affective disorder should not ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 3Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... Organization (NGO), sent over $3,000,000 of vitally needed medical supplies to ... ... -- In a continent often defined by man-made conflicts and natural ... success stories. Among the 53 countries in Africa there ...
... used as traditional remedies for hundreds of years. Among ... in treatment of hepatitis, inflammation, osteomyelitis and gynecological diseases ... barbata have growth inhibitory effects on a number ... of lung, breast and digestive system cancer, hepatoma, and ...
... Scantek Medical, Inc. (Pink Sheets: SKML)("Scantek") announced ... voluntary petition in the United States Bankruptcy Court pursuant ... States Code. Scantek also announced today that it ... Sensor product ("BreastCare") to a medical equipment supplier for ...
... genes initially appeared to be statistically significantly associated with ... individual studies are pooled, however, few DNA repair gene ... to a field synopsis published in the December 30 ... Cancer Institute. , Because DNA damage is associated ...
... didn,t halt women,s risk of developing disease , , TUESDAY, ... the supposed cancer-fighting powers of vitamins C and E, ... don,t prevent the disease in women. , And another ... new study found. , , "Simply taking antioxidant supplements ...
... Boston resident Barbara Gilchrest, MD, a member of ... and professor and chairman-emeritus of the Department of Dermatology ... recently named one of America,s Top Doctors by Castle ... recognized by consumers seeking high-quality medical care, is a ...
Cached Medicine News:Health News:Good News in Africa: Beyond the headlines 2Health News:Scantek Medical Files for Chapter 11 Voluntary Bankruptcy and Receives Orders for the Sale of BreastCare(TM) 2Health News:Few DNA repair genes maintain association with cancer in field synopsis 2Health News:Vitamins Fail to Prevent Cancer: Study 2Health News:Vitamins Fail to Prevent Cancer: Study 3Health News:BMC, Boston University School of Medicine dermatologist named one of America's Top Doctors 2
... The Cryostage freezing stage is a refrigerated ... object holder, primarily for use with the 8000 ... other sledge microtomes. ,The refrigerated stage gives a ... the surface is ridged to provide good adhesion ...
... work, it is necessary to cool a specimen ... be fitted to most microtomes and will permit ... depending on conditions. The equipment consists of a ... stage is best suited for operation with a ...
... Freezing Stages fit easily onto most microtomes. ... need only the AC supply and a trickle ... starts immediately and can be maintained indefinitely. ... temperatures can be set for different kinds of ...
... MNL 4404 & 4405 series Freezing Stages ... devices have no moving parts and need only ... water for operation. Freezing starts immediately ... is adjustable so that optimum cutting temperatures can ...
Medicine Products: